Your search for smoking cessation returned 67 results

Results from a placebo-controlled study evaluating Chantix (varenicline; Pfizer) in pediatric patients 12-16 years of age showed that the smoking cessation treatment was not associated with a significant increase in abstinence rates in this patient population.

Benefits of smoking cessation medications decline over the first year.

An analysis conducted by UC San Francisco (UCSF) researchers found that rather than aid smoking cessation, e- cigarette users were 28% less likely to quit smoking traditional cigarettes.

According to new research published in the Journal of Clinical Psychiatry, smokers who are addicted to cocaine or methamphetamine can quit smoking while being treated for their stimulant addiction, without interfering.

According to a study in the journal Nicotine and Tobacco Research, the smoking cessation treatment varenicline is more effective for women in short and immediate outcomes compared to men, but is equally effective for both with longer outcomes.

A bacterial enzyme may be a future candidate in smoking cessation, according to a new study led by researchers at The Scripps Institute.

The data showed TNP was significantly more effective vs. no medication assisted quit attempts for males (odds ratio [OR] 1.37, 95% CI: 1.02, 1.83; P=0.03) but not for females (OR 0.96, 95% CI: 0.71, 1.31; P=0.82).

Adverse events observed among adolescent smokers in the study were comparable to those seen in adult studies.

The FDA determined the benefits of this smoking cessation therapy outweighed the potential risks.

The National Comprehensive Cancer Network (NCCN) has released Clinical Practice Guidelines in Oncology for Smoking Cessation.